ANL vs. MORF, AVDL, SUPN, DVAX, RCUS, XNCR, PCRX, BLTE, KNSA, and SYRE
Should you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Morphic (MORF), Avadel Pharmaceuticals (AVDL), Supernus Pharmaceuticals (SUPN), Dynavax Technologies (DVAX), Arcus Biosciences (RCUS), Xencor (XNCR), Pacira BioSciences (PCRX), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical preparations" industry.
Adlai Nortye (NASDAQ:ANL) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.
35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 94.3% of Morphic shares are owned by institutional investors. 25.6% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Adlai Nortye presently has a consensus price target of $30.00, suggesting a potential upside of 313.22%. Morphic has a consensus price target of $51.50, suggesting a potential upside of 69.58%. Given Adlai Nortye's stronger consensus rating and higher possible upside, analysts clearly believe Adlai Nortye is more favorable than Morphic.
Adlai Nortye has higher earnings, but lower revenue than Morphic.
Morphic received 74 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 59.54% of users gave Morphic an outperform vote.
In the previous week, Morphic had 2 more articles in the media than Adlai Nortye. MarketBeat recorded 3 mentions for Morphic and 1 mentions for Adlai Nortye. Morphic's average media sentiment score of 1.02 beat Adlai Nortye's score of 0.93 indicating that Morphic is being referred to more favorably in the news media.
Adlai Nortye's return on equity of 0.00% beat Morphic's return on equity.
Summary
Morphic beats Adlai Nortye on 7 of the 12 factors compared between the two stocks.
Get Adlai Nortye News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adlai Nortye Competitors List
Related Companies and Tools
